Deadline of December, 31th, 2017. Almirall is offering financial and scientific support to develop novel pharmacologically validated in vitro and in vivo research translational preclinical models in skin diseases.
All proposals submitted before the deadline of December, 31th, 2017 will be considered for up to €100,000 worth of funding.
Almirall, S.A. (ALM), through its open innovation platform AlmirallShare, is now accepting proposals for translational preclinical models to help fight key skin diseases —such as psoriasis, atopic dermatitis, acne, and rosacea— for the chance to get support from Almirall.
These can be in vitro assays or in vivo models relevant in the context of the disease that have translatable clinical endpoints. All proposals submitted before the deadline of December, 31th, 2017 will be considered for up to €100,000 worth of funding.
After the submissions of their proposals, the Almirall team will review them and suggest the best way for the selected proposals to progress. We are here to help your idea grow, and provide mentorship to help your initial proposal meet project criteria, as well as support along your journey.
The clock is ticking towards the deadline for this first Almirall challenge. We will be glad to collaborate with you.
Don’t let your ideas miss out on a chance to change the lives of people with skin diseases!
AlmirallShare first Scientific call: Preclinical Models
Date: from 12/09/17 to 31/12/17
Participants: universities, research entities, biotechs, start-ups, hospitals.
Grants: €25.000 to €100.000
AlmirallShare is an open innovation platform designed by Almirall to facilitate the establishment of collaborations in dermatological research and find innovative solutions in skin health. This initiative aims to promote collaborations between partners around the world, whether they be universities, start-ups, or research entities.
Scientists at Universities, public or private research institutions, hospitals, and biotechnology companies are invited to participate and address the dermatological challenges posted in sharedinnovation.almirall.com
Almirall is a leading skin-health focused global pharmaceutical company that partners with healthcare professionals, applying Science to provide medical solutions to patients & future generations. Our efforts are focused on fighting against skin health diseases and helping people feel and look their best. We support healthcare professionals in its continuous improvement, bringing our innovative solutions where they are needed.
The company, founded in 1943 and with headquarters in Barcelona, is listed on the Spanish Stock Exchange (ticker: ALM). Almirall has become a key element of value creation to society according to its commitment with its major shareholders and its decision to help others, to understand their challenges and to use Science to provide them with solutions for real life. Total revenue in 2016 was 859.3 million euros and more than 2,000 employees are devoted to Science.
For more information, please visit almirall.com linkedin.com/company/almirall
Media contact: Cohn & Wolfe
Adriana Ibargüen (Adriana.email@example.com)/RebecaRocha (Rebeca.firstname.lastname@example.org)
Tel.: (+34) 91 531 42 67
Investors & Corporate communication contact: Almirall
Pablo Divasson del Fraile
Tel (+34) 93 291 30 87